Sarepta says early filing for DMD gene therapy may be back on

Sarepta says early filing for DMD gene therapy may be back on

Source: 
Pharmaforum
snippet: 

The development of gene therapies for Duchenne muscular dystrophy has proved to be challenging, but one of the key players – Sarepta – thinks it may have the clinical data needed to file for regulator approval.